The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms

Biology of Reproduction

Volumn 87, Issue 2, 2012, Pages

  Laresgoiti Servitje, Estibalitz ^a   Gomez Lopez, Nardhy ^b,c,d  

^a UNIVERSIDAD PANAMERICANA   (Mexico)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ALBERTA   (Canada)

^d INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

Angiogenic factor; Angiotensin II; Angiotensin II type 1 receptor autoantibodies; At1 AA; Hypoxia; Preeclampsia; Reninangiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II ANTIBODY; ANGIOTENSIN II TYPE 1 RECEPTOR ANTIBODY; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 16; INTERLEUKIN 6; PLACENTAL GROWTH FACTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

AUTOIMMUNITY; B LYMPHOCYTE; HUMAN; HYPOXIA; IMMUNE SYSTEM; NONHUMAN; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANGIOGENIC PROTEINS; ANOXIA; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RAS PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 84869452369     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.112.099861     Document Type: Short Survey

References (105)

1. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008; 51: 1002-1009.
2. Davey D, Macgillivray I, James MR, Richard JL. Classification of hypertensive disorders in pregnancy. Lancet 1989; 334:112-113.
3. James JL, Stone PR, Chamley LW. Cytotrophoblast differentiation in the first trimester of pregnancy: evidence for separate progenitors of extravillous trophoblasts and syncytiotrophoblast. Reproduction 2005; 130:95-103.
4. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93:1049-1059.
5. Simmons LA, Hennessy A, Gillin AG, Jeremy RW. Uteroplacental blood flow and placental vascular endothelial growth factor in normotensive and pre-eclamptic pregnancy. Br J Obstet Gynaecol 2000; 107:678-685.
6. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96:950-955.
7. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95:884-891.
8. Laresgoiti-Servitje E, Gómez-López N, Olson DM. An immunological insight into the origins of pre-eclampsia. Hum Reprod Update 2010; 16: 510-524.
9. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952.
10. Jauniaux E, Watson AL, Hempstock J, Bao Y-P, Skepper JN, Burton GJ. Onset of maternal arterial blood flow and placental oxidative stress: a possible factor in human early pregnancy failure. Am J Pathol 2000; 157: 2111-2122.
11. Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher SJ. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004; 114: 744-754.
12. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extraplacental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26:563-573.
13. Rajakumar A, Jeyabalan A, Markovic N, Ness R, Gilmour C, Conrad KP. Placental HIF-1falphag, HIF-2falphag, membrane and soluble VEGF receptor-1 proteins are not increased in normotensive pregnancies complicated by late-onset intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol 2007; 293:R766-774.
14. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFfbetag3. J Clin Invest 2000; 105:577-587.
15. Nishi H, Nakada T, Hokamura M, Osakabe Y, Itokazu O, Huang LE, Isaka K. Hypoxia-inducible factor-1 transactivates transforming growth factor-fbetag3 in trophoblast. Endocrinology 2004; 145:4113-4118.
16. Evans PW, Wheeler T, Anthony FW, Osmond C. A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod 1998; 13:1057-1062.
17. Tissot van Patot MC, Bendrick-Peart J, Beckey VE, Serkova N, Zwerdlinger L. Greater vascularity, lowered HIF-1/DNA binding, and elevated GSH as markers of adaptation to in vivo chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2004; 287:L525-L532.
18. Fujita D, Tanabe A, Sekijima T, Soen H, Narahara K, Yamashita Y, Terai Y, Kamegai H, Ohmichi M. Role of extracellular signal-regulated kinase and AKT cascades in regulating hypoxia-induced angiogenic factors produced by a trophoblast-derived cell line. J Endocrinol 2010; 206: 131-140.
19. Nishimoto F, Sakata M, Minekawa R, Okamoto Y, Miyake A, Isobe A, Yamamoto T, Takeda T, Ishida E, Sawada K, Morishige K-i, Kimura T. Metal transcription factor-1 is involved in hypoxia-dependent regulation of placenta growth factor in trophoblast-derived cells. Endocrinology 2009; 150:1801-1808.
20. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W, Murphy BJ. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 2001; 61:2696-2703.
21. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. the CSG. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
22. Gould PS, Gu M, Liao J, Ahmad S, Cudmore MJ, Ahmed A, Vatish M. Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. Hypertension 2010; 56:172-178.
23. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108:1063-1070.
24. Mano Y, Kotani T, Shibata K, Matsumura H, Tsuda H, Sumigama S, Yamamoto E, Iwase A, Senga T, Kikkawa F. The loss of endoglin promotes the invasion of extravillous trophoblasts. Endocrinology 2011; 152:4386-4394.
25. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
26. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 2009; 24:147-158.
27. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93:260-266.
28. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1085-R1093.
29. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
30. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49:818-824.
31. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 2012; 26(4):236-241.
32. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart J-M. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23:1407-1415.
33. Thomas CP, Andrews JI, Raikwar NS, Kelley EA, Herse F, Dechend R, Golos TG, Liu KZ. A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J Clin Endocrinol Metab 2009; 94: 2524-2530.
34. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008; 102:1566-1574.
35. Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005; 26:210-217.
36. Davidge ST, Stranko CP, Roberts JM. Urine but not plasma nitric oxide metabolites are decreased in women with preeclampsia. Am J Obstet Gynecol 1996; 174:1008-1013.
37. Fitzgerald DJ, Entman SS, Mulloy K, FitzGerald GA. Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation 1987; 75:956-963.
38. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 2002; 283:R29-45.
39. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278:12605-12608.
40. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A 2007; 104: 14448-14453.
41. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007; 92: 2672-2679.
42. Tskitishvili E, Sharentuya N, Temma-Asano K, Mimura K, Kinugasa-Taniguchi Y, Kanagawa T, Fukuda H, Kimura T, Tomimatsu T, Shimoya K. Oxidative stress-induced S100B protein from placenta and amnion affects soluble Endoglin release from endothelial cells. Mol Hum Reprod 2010; 16:188-199.
43. Anton L, Merrill DC, Neves LAA, Stovall K, Gallagher PE, Diz DI, Moorefield C, Gruver C, Ferrario CM, Brosnihan KB. Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension 2008; 51:1066-1072
44. Morgan T, Craven C, Ward K. Human spiral artery renin-angiotensin system. Hypertension 1998; 32:683-687.
45. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007; 49:604-611.
46. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki M, et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 1993; 4:59-61.
47. Wang Y, Gu Y, Lewis DF. Endothelial angiotensin II generation induced by placenta-derived factors from preeclampsia. Reprod Sci 2008; 15: 932-938.
48. Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, Wallukat G, Luft FC, Redman CWG, Dechend R. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 2009; 53:393-398.
49. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55: 386-393.
50. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14:855-862.
51. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
52. Dechend R, Homuth V, Wallukat G, Muller DN, Krause M, Dudenhausen J, Haller H, Luft FC. Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Investig 2006; 13:79-86.
53. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day M-C, Ramin SM, Ahmed A, Kellems RE, Xia Y. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated Tcells signaling. Hypertension 2008; 51:1010-1019.
54. Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factorfalphag signaling. Hypertension 2010; 55:1246-1253.
55. Zhou CC, Irani RA, Dai Y, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol 2011; 186:6024-6034.
56. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN Jr, Bennett WA. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999; 181:915-920.
57. Wang Y, Walsh SW. TNFa concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996; 32: 157-169.
58. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B. The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 2010; 23:911-916.
59. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, Cheng X, Zhang M, Ma XL, Liu H. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens 2008; 26:1629-1635.
60. Parrish MR, Wallace K, Tam Tam KB, Herse F, Weimer A, Wenzel K, Wallukat G, Ray LF, Arany M, Cockrell K, Martin JN, Dechend R, et al. Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension. Am J Hypertens 2011; 24:835-840.
61. LaMarca B, Wallace K, Herse F, Wallukat G, Martin JN, Weimer A, Dechend R. Hypertension in response to placental ischemia during pregnancy. Hypertension 2011; 57:865-871.
62. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, Markovic N, Thadhani R, Luft FC, Dechend R. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007; 49:612-617.
63. Irani RA, Zhang Y, Blackwell SC, Zhou CC, Ramin SM, Kellems RE, Xia Y. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J Exp Med 2009; 206:2809-2822.
64. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302:575-581.
65. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381:751-758.
66. Keenan RA, De Riva A, Corleis B, Hepburn L, Licence S, Winkler TH, Martensson IL. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 2008; 321:696-699.
67. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
68. Seo SJ, Fields ML, Buckler JL, Reed AJ, Mandik-Nayak L, Nish SA, Noelle RJ, Turka LA, Finkelman FD, Caton AJ, Erikson J. The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity 2002; 16:535-546.
69. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008; 29:249-260.
70. Vlková B, Szemes T, Minárik G, Turnǎ J, Celec P. Circulating free fetal nucleic acids in maternal plasma and preeclampsia. Med Hypotheses 2010; 74:1030-1032.
71. LaMarca B, Brewer J, Wallace K. IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate? Int J Infereron Cytokine Mediator Res 2011; 2011:59-64.
72. Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010; 88:253-262.
73. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20:253-300.
74. Leung TN, Zhang J, Lau TK, Chan LYS, Lo YMD. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001; 47:137-139.
75. Niu MC, Niu LC, Guha A. The entrance of exogenous RNA into the mouse ascites cell. Proc Soc Exp Biol Med 1968; 128:550-555.
76. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-607.
77. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202:1171-1177.
78. Benyo DF, Smarason A, Redman CWG, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001; 86:2505-2512.
79. Gu Y, Lewis DF, Deere K, Groome LJ, Wang Y. Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in women with preeclampsia. J Immunol 2008; 181:4418-4422.
80. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, Hibbs ML. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J Immunol 2010; 184: 1348-1360.
81. Eriksson U, Kurrer MO, Schmitz N, Marsch SC, Fontana A, Eugster HP, Kopf M. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 2003; 107:320-325.
82. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18:565-570.
83. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XYR. Antiinterleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119: 296-305.
84. Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autimmun 2010; 11:1-26.
85. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108:253-261.
86. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205:331-337.
87. Masli S, Turpie B. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology 2009; 127:62-72.
88. Zakharova M, Ziegler HK. Paradoxical anti-inflammatory actions of TNF-a: inhibition of IL-12 and IL-23 via TNF Receptor 1 in macrophages and dendritic cells. J Immunol 2005; 175:5024-5033.
89. Germain SJ, Sacks GP, Soorana SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178: 5949-5956.
90. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 2009; 296:R208-216.
91. von Dadelszen P, Hurst G, Redman CWG. Supernatants from co-cultured endothelial cells and syncytiotrophoblast microvillous membranes activate peripheral blood leukocytes in vitro. Hum Reprod 1999; 14: 919-924.
92. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin ii-induced inflammation. J Am Soc Nephrol 2007; 18: 1093-1102.
93. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor falphag in pregnant rats. Hypertension 2008; 52:1168-1172.
94. Holmlund U, Wahamaa H, Bachmayer K, Bremme N, Sverremark-Ekström E, Palmblad K. The novel inflammatory cytokine high mobility group box protein 1 (HMGB1) is expressed by human term placenta. Immunology 2007; 122:430-437.
95. Schmidt AP, Tort ABL, Amaral OB, Schmidt AP, Walz R, Vettorazzi-Stuckzynski J, Martins-Costa SH, Ramos JGL, Souza DO, Portela LVC. Serum S100B in pregnancy-related hypertensive disorders: a case-control study. Clin Chem 2004; 50:435-438.
96. Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205:3007-3018.
97. BellDA, Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol 1991; 60:13-26.
98. Crocker IP, Cooper S, Ong SC, Baker PN. Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am J Pathol 2003; 162:637-643.
99. Jensen F, Wallukat G, Herse F, Budner O, El-Mousleh T, Costa S-D, Dechend R, Zenclussen AC. CD19+CD5+ Cells as indicators of preeclampsia. Hypertension 2012; 59(4):861-868.
100. Sato S, Ono N, Steeber D, Pisetsky D, Tedder T. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996; 157:4371-4378.
101. Ebeling SB, Schutte ME, Logtenberg T. The majority of human tonsillar CD5+ B cells express somatically mutated V kappa 4 genes. Eur J Immunol 1993; 23:1405-1408.
102. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009; 9:845-857.
103. Casali P, Burastero S, Nakamura M, Inghirami G, Notkins A. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236:77-81.
104. Dauphinée M, Tovar Z, Talal N. B cells expressing cd5 are increased in sjögren's syndrome. Arthritis Rheum 1988; 31:642-647.
105. Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin Immunol Immunopathol 1990; 56:219-225